Status:
COMPLETED
Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics
Lead Sponsor:
University of Dundee
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Asthma
Eligibility:
All Genders
5-18 years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether patients with asthma who carry a genotype associated with adverse outcomes with long-acting beta-2 agonists like salmeterol show greater benefit from ...
Detailed Description
Background/Rationale: The presence of the homozygous Arg/Arg genotype at position 16 of the β2-receptor (prevalence 15-17% in UK/US populations) confers relative protection against down-regulation by...
Eligibility Criteria
Inclusion
- All children and adolescents (5-18 years) with asthma in Tayside (Scotland) known:
- To carry the Arg/Arg-16 genotype and
- Currently on inhaled steroids and
- Inhaled bronchodilators according to need will be telephoned or contacted through home visits to establish if they have had:
- Any school absences from asthma or
- Out-of-hours visits to GP/hospital visits or admissions due to asthma over the previous 12 months.
Exclusion
- The presence of serious respiratory or multi-system disease (e.g. cystic fibrosis, cancer under current treatment)
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00655616
Start Date
August 1 2007
End Date
December 1 2009
Last Update
March 24 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maternal and Child Health Sciences, Ninewells Hospital and Medical School
Dundee, Tayside, United Kingdom, DD1 9SY